Cargando…

Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany

INTRODUCTION: Metformin is an established first-line treatment for patients with type 2 diabetes mellitus (T2DM), but treatment intensification with other oral antidiabetes drugs (OADs) is usually required over time. Effectiveness of diabetes control with vildagliptin and vildagliptin/metformin was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göke, Rüdiger, Bader, Giovanni, Dworak, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065295/ https://www.ncbi.nlm.nih.gov/pubmed/24643724 http://dx.doi.org/10.1007/s13300-014-0060-4

Ejemplares similares

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
por: Mathieu, C, et al.
Publicado: (2013)

Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study
por: Saab, Charles, et al.
Publicado: (2015)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes
por: Blüher, Matthias, et al.
Publicado: (2014)

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
por: Brandon, Rebecca, et al.
Publicado: (2023)

Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data
por: Kamenov, Zdravko
Publicado: (2014)

Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study
por: Berndt-Zipfel, Christine, et al.
Publicado: (2013)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
por: Mathieu, Chantal, et al.
Publicado: (2008)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting
por: Yavropoulou, M. P., et al.
Publicado: (2015)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study
por: Simon, Dominique, et al.
Publicado: (2014)

The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial
por: Yamamoto, Hiroyuki, et al.
Publicado: (2021)

Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study
por: Zang, Li, et al.
Publicado: (2019)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Glucose Absorption in Gestational Diabetes Mellitus During an Oral Glucose Tolerance Test
por: Anderwald, Christian, et al.
Publicado: (2011)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study
por: Blüher, Matthias, et al.
Publicado: (2015)

Vildagliptin improves high glucose‐induced endothelial mitochondrial dysfunction via inhibiting mitochondrial fission
por: Liu, Hengdao, et al.
Publicado: (2018)

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
por: Tura, Andrea, et al.
Publicado: (2015)

Prediction of Glucose Tolerance without an Oral Glucose Tolerance Test
por: Babbar, Rohit, et al.
Publicado: (2018)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
por: Zhang, Qian, et al.
Publicado: (2017)

Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia
por: Jamieson, Emma L., et al.
Publicado: (2019)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
por: Cosenso-Martin, Luciana Neves, et al.
Publicado: (2020)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_8vncj1ogg8tn6sj4014jlg08k2